Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 Dichloride Long-term Follow-up Program
jRCT2080224668Phase 3Completed
- Sponsor
- Bayer
- Start
- May 2019
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
01
Overview
Phase 3, open-label trial of radium-223 dichloride in breast cancer and prostate cancer (PCa) (2 arms), sponsored by Bayer. Started May 2019; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
breast cancerprostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2080224668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224668.